[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fb6unic9zGevxmntLtLhAWo8OOmmeHIOy_XWBk4_J8dM":8,"$ftvDYpeK8FTsqoknReKfbxQHPfy9ra4Qa7DeNaS666uE":56,"$f4lNTa6k6ivltnRH3WSyK96VbLOCLbcgsK-6K3QKXRiU":60},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":55},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":33,"menus":34,"menuId":36,"type":43,"quality":54,"commentCount":21,"isComment":43},75309,870524,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//CGYabC0HKWAPPesgIv0r6dsFTD1mgA24.png","郭宇","安吉县人民医院","肿瘤科","副主任医师",20,0,"胰腺癌药品实用用药指南：安全、规范、科学","","https://ystcdn.venuertc.com/venue/AI/0ceb9f4b-f223-4b75-afb0-cba1fa2ddcbb.jpg","\u003Cdiv class=\"drugguide-container\">\n  \u003Ch1 id=\"material_title\" class=\"drugguide-title\">胰腺癌药品实用用药指南：安全、规范、科学\u003C/h1>\n  \u003Cdiv class=\"drugguide-intro\">\n    说起来，抗肿瘤药物的选择和使用环节患者及家人都十分关心。以胰腺癌治疗常用的几类药物为例，剂型多样、使用要求严格，合理搭配和注意用药细节才能确保疗效最大化和安全风险最小化。本文将通过9个关键环节，深入细致梳理胰腺癌治疗常用药物的正确用药方法、剂型特点、注意事项与风险防范，让大家能一目了然记住常见问题解决要点。\n  \u003C/div>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg1\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>1\u003C/span> 常用药物的成分及分类 🌱\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      胰腺癌治疗中经常使用的药物可按作用机制分为：\u003Cstrong>细胞毒性化疗药\u003C/strong>（如吉西他滨gemcitabine、紫杉醇类paclitaxel）、\u003Cstrong>靶向治疗药\u003C/strong>（如厄洛替尼erlotinib）、\u003Cstrong>免疫检查点抑制剂\u003C/strong>（如纳武利尤单抗nivolumab）等。\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>吉西他滨（Gemcitabine）\u003C/b>：注射液剂型，常为1 g/瓶。其分子结构易被细胞吸收，是最经典的一线化疗药物之一。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>紫杉醇（Paclitaxel）\u003C/b>：也多为注射液，常规规格有100 mg/瓶及常规溶液/白蛋白结合型两种剂型。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>厄洛替尼（Erlotinib）\u003C/b>：口服片剂，常见为100 mg/片和150 mg/片。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>纳武利尤单抗（Nivolumab）\u003C/b>：注射液剂型，规格40 mg/瓶等。\n        \u003C/li>\n      \u003C/ul>\n      正确认识各类药品的主要成分及剂型，是选用和管理环节的第一步。\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg2\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>2\u003C/span> 药物作用机制一览🔬\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      用于胰腺癌治疗的药物机制各有不同，影响细胞增殖或调控免疫反应：\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>吉西他滨：\u003C/b> 为一种脱氧核苷类似物，通过抑制DNA合成，使细胞无法正常分裂增殖，从而杀伤癌细胞。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>紫杉醇：\u003C/b> 作用于微管蛋白，破坏细胞有丝分裂过程，导致肿瘤细胞凋亡。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>厄洛替尼：\u003C/b> 属于EGFR抑制剂，通过阻断上皮生长因子受体信号传递，干扰肿瘤细胞生长。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>纳武利尤单抗：\u003C/b> 是免疫检查点抑制剂，解除肿瘤对免疫系统的“刹车”，恢复T细胞识别和清除肿瘤细胞的能力。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-tip\">合理搭配不同作用机制的药物，有助于提升治疗协同效果。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg3\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>3\u003C/span> 正确使用方法与给药时间⏰\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      各种药物的给药时间和方式存在显著差异，正确操作至关重要：\n      \u003Cul>\n        \u003Cli>\u003Cb>吉西他滨：\u003C/b> 需通过静脉点滴缓慢注射（常为半小时至一小时）；不宜自行更改速度。\u003C/li>\n        \u003Cli>\u003Cb>紫杉醇：\u003C/b> 通常也为静脉点滴，滴注前需提前做过敏试验，遵医嘱稀释后滴入，时间短则30分钟，长则3小时不等。\u003C/li>\n        \u003Cli>\u003Cb>厄洛替尼：\u003C/b> 口服，\u003Cb>须空腹服用\u003C/b>（即饭前或饭后1小时），吞服整片，不可掰开或咀嚼。\u003C/li>\n        \u003Cli>\u003Cb>纳武利尤单抗：\u003C/b> 作为注射液静脉滴注，常按体重固定剂量，用药频率遵医嘱。\u003C/li>\n      \u003C/ul>\n      正确做法：遵照医护人员操作规范，不随意更改服用时间、服药方式，也不可擅自增加或减少用量。\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg4\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>4\u003C/span> 剂型差异与服用技巧💊\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      不同药物剂型要求不同操作技巧：\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>吉西他滨/紫杉醇：\u003C/b> 均为注射剂型，由专业护士配置后静脉注射；配药时严格无菌操作。\u003Cbr>\n          \u003Cspan class=\"drugguide-tip\">如药液出现混浊、漂浮物、变色应立即弃用。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>厄洛替尼：\u003C/b> 为口服片剂，必须整片吞服。为避免与胃酸抑制药干扰，应单独服用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>纳武利尤单抗：\u003C/b> 注射液开封后需立即使用，剩余药液不得保存重复使用。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-emphasize\">正确做法：遇到药品包装损坏、粒片破碎、药液异常请勿使用。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg5\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>5\u003C/span> 药物相互作用与间隔服用🧩\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      一些抗肿瘤药容易与其他药物产生相互作用，错误联合可能导致副作用或降低疗效：\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>厄洛替尼：\u003C/b> 遇质子泵抑制剂、抗酸剂会降低体内药物浓度，应尽量避免同服。如必须合用须与抗酸药间隔数小时。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>吉西他滨：\u003C/b> 与其他细胞毒药物并用时应严格遵医嘱调整剂量，勿自行变更顺序或用量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>紫杉醇：\u003C/b> 与CYP450酶抑制药合用可改变血药浓度，特别是某些抗生素、抗真菌药、心脏药需谨慎。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>纳武利尤单抗：\u003C/b> 与其他免疫抑制剂同用可能增加免疫相关副作用风险。一定要告知医生所有正在使用的药物。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-tip\">正确做法：每次就诊时主动报告正在服用的全部药品和保健品清单。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg6\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>6\u003C/span> 特殊人群剂量调整与用药安全👵👦\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      特殊人群需特别考虑剂量调整及用药风险：\n      \u003Cul>\n        \u003Cli>\n          老年人：肝肾功能易下降，部分药物（如吉西他滨、紫杉醇）需个体化调整剂量和延长给药间隔。\n          \u003Cspan class=\"drugguide-tip\">案例：一名61岁男性患者在调整吉西他滨剂量后，副反应明显缓解，疗程顺利完成。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          肝肾功能不全者：给药前须查相关功能指标，不符合要求时推迟或降低剂量。\n        \u003C/li>\n        \u003Cli>\n          孕妇、哺乳期妇女：大部分抗肿瘤药物存在致畸、致胚风险，禁止使用。生育期妇女用药时一定要采取严格避孕措施。\n        \u003C/li>\n        \u003Cli>\n          儿童患者：如无权威指南推荐，慎重使用，需进行专业风险评估。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-emphasize\">正确做法：特殊人群须严密监测用药反应，出现异常立即报告医生。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg7\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>7\u003C/span> 常见不良反应与处理方法⚠️\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      抗肿瘤药物常见不良反应包括骨髓抑制、皮肤反应、消化道不适等：\n      \u003Cul>\n        \u003Cli>吉西他滨可引起白细胞、血小板下降（骨髓抑制发生率高于25% \u003Cspan class=\"drugguide-refdata\">[1]\u003C/span>），如体温升高、出血倾向需立即就医。\u003C/li>\n        \u003Cli>紫杉醇易出现外周神经炎、关节疼痛、脱发等。\u003C/li>\n        \u003Cli>厄洛替尼易导致皮疹、腹泻，偶有严重皮肤毒性。\u003C/li>\n        \u003Cli>纳武利尤单抗部分患者会有皮肌炎、肺炎等免疫相关反应，需随访血象和肺功能。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-tip\">正确做法：用药期间自觉出现突发不适时切勿自行处理，应第一时间联络医疗人员。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg8\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>8\u003C/span> 药品储存与有效期管理🌡️\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      精确掌握药品储存要求，是保障药效的前提：\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>吉西他滨、紫杉醇、纳武利尤单抗：\u003C/b>需避光、冷藏（2-8°C），勿放在阳台、窗台等暴晒或高温处。药品开封后剩余部分应立即弃去。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>厄洛替尼：\u003C/b>室温密封保存，避免潮湿。瓶装药需旋紧盖，勿与食品化学品同存。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-tip\">过期药品不可使用，建议统一交由药房或医疗机构回收。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg9\">\u003C/div>\n    \u003Ch2 class=\"drugguide-subtitle\">\u003Cspan>9\u003C/span> 漏服和过量应对策略⏳\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      漏服和过量用药的正确处理方法对于预防风险非常关键：\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>厄洛替尼：\u003C/b> 若漏服一剂，发现后如临近下次服药时间，直接跳过，不可双倍补服。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>注射药物：\u003C/b> 漏用一剂后不可随意补用，需联系医护人员安排后续计划。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>出现过量：\u003C/b> 如误服或误用超剂量，应立即寻求医疗帮助，不可拖延。临床研究发现，超剂量可显著增加不良反应风险 \u003Cspan class=\"drugguide-refdata\">[2]\u003C/span>。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-tip\">正确做法：养成记录用药的好习惯，对每次用药情况做简要备忘，避免遗忘。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg10\">\u003Cbr>\u003C/div>\u003Ch2 class=\"drugguide-subtitle\"> 实际用药小案例分享📝\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cul>\n        \u003Cli>\n          临床上遇到一位61岁男性患者服用吉西他滨时，因未按规定时间静脉滴注，出现局部静脉刺激感，随后调整滴注速度后症状消失。\n        \u003C/li>\n        \u003Cli>\n          另一位患者在口服厄洛替尼期间，曾与抗酸药一起服用，导致药效下降，提示同步用药需严格遵医嘱调整间隔。\n        \u003C/li>\n        \u003Cli>\n          有患者在使用纳武利尤单抗过程中出现皮肤瘙痒，及时反馈后医生介入处理，症状基本缓解，未影响治疗进度。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drugguide-tip\">\u003Cb>经验分享：\u003C/b>用药中的每个细节都值得关注，良好的沟通和监督可显著减少风险。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg11\">\u003Cbr>\u003C/div>\u003Ch2 class=\"drugguide-subtitle\"> 核心要点回顾与安全建议💡\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      总体来说，胰腺癌用药涉及多类药物与复杂流程，强调规范操作和细致管理。尤其要牢记以下要点：\n      \u003Cul>\n        \u003Cli>保证用药流程全程获专业指导，切忌自行增减剂量、换药或更改服用顺序。\u003C/li>\n        \u003Cli>每类药品的服用方式、剂量管理和储存环境都非常严格，务必查验证明再操作。\u003C/li>\n        \u003Cli>如遇用药期间任何突发症状，必须停止自作主张，第一时间遵医嘱处理。\u003C/li>\n      \u003C/ul>\n      再次强调：\u003Cb>药品安全源自细致的每个环节\u003C/b>，相信科学指南，方能呵护健康。遇到用药疑问，及时向医生或药师咨询，是大家用药路上的“最佳搭档”。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"drugguide-section\">\n    \u003Cdiv class=\"drugguide-section-bg bg12\">\u003Cbr>\u003C/div>\u003Ch2 class=\"drugguide-subtitle\"> 参考文献\u003C/h2>\n    \u003Cdiv class=\"drugguide-content drugguide-references\">\n      \u003Col>\n        \u003Cli>\n          Von Hoff, D. D., Ervin, T., Arena, F. P., et al. (2013). \"Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine.\" New England Journal of Medicine, 369(18):1691-1703.\n        \u003C/li>\n        \u003Cli>\n          Saif, M.W., & Syrigos, K.N. (2016). \"Overcoming treatment challenges in pancreatic cancer: Preclinical and clinical insights.\" Cancer Chemotherapy and Pharmacology, 78(4): 673-685.\n        \u003C/li>\n        \u003Cli>\n          Moore, M.J., Goldstein, D., Hamm, J., et al. (2007). \"Erlotinib plus Gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.\" J Clin Oncol, 25(15):1960-1966.\n        \u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.drugguide-container {\n  max-width: 840px;\n  margin: 38px auto;\n  padding: 22px 28px 38px 28px;\n  background: #fbfbfa;\n  border-radius: 17px;\n  box-shadow: 0 7px 28px 0 rgba(30,40,50,0.07);\n  font-family: 'Segoe UI', 'PingFang SC', 'Microsoft Yahei', Arial, sans-serif;\n  color: #232323;\n  line-height: 1.85;\n  font-size: 17px;\n}\n.drugguide-title {\n  font-size: 2.1em;\n  font-weight: bold;\n  color: #316282;\n  letter-spacing: 1px;\n  margin-top: 26px;\n  margin-bottom: 23px;\n  text-align: center;\n  padding-bottom: 11px;\n  border-bottom: 2px solid #b6d4ec;\n  box-shadow: 0 2px 15px 0 rgba(70,145,200,0.05);\n}\n.drugguide-intro {\n  font-size: 1.1em;\n  color: #46739b;\n  background: linear-gradient(90deg, #eaf3fc 50%, #fbfbfa 100%);\n  border-radius: 8px;\n  padding: 15px 20px 12px 20px;\n  margin-bottom: 32px;\n  box-shadow: 0 1px 6px 0 rgba(106,175,227,0.09);\n}\n.drugguide-section {\n  margin-bottom: 38px;\n  position: relative;\n}\n.drugguide-section-bg {\n  position: absolute;\n  left: 0; right: 0; top: 0; bottom: 0;\n  z-index: 0;\n  border-radius: 13px;\n  opacity: 0.18;\n  height: 100%;\n}\n.bg1 {background: url(\"data:image/svg+xml,%3Csvg width='520' height='50'%3E%3Cellipse fill='%239be7ff' cx='85' cy='25' rx='100' ry='15'/%3E%3C/svg%3E\") repeat-x top 10px;}\n.bg2 {background: linear-gradient(93deg,#e8f2fe 70%,#c4e1fa 100%);}\n.bg3 {background: linear-gradient(90deg,#f4f7fb 85%,#f2ede7 100%);}\n.bg4 {background: linear-gradient(90deg,#a7d6f9 10%,#fffbe9 95%);}\n.bg5 {background: linear-gradient(87deg,#e7f8fe 60%,#f3f7f6 100%);}\n.bg6 {background: linear-gradient(99deg,#eaf3fc 80%,#e3ead4 100%);}\n.bg7 {background: linear-gradient(97deg,#f0f7fd 77%,#f9e6de 100%);}\n.bg8 {background: linear-gradient(92deg,#f8fcf9 86%,#e2ecf6 100%);}\n.bg9 {background: linear-gradient(90deg,#eaf3fc 50%,#fcfcfa 100%);}\n.bg10 {background: linear-gradient(184deg,#faf3e2 70%,#e4f4fa 100%);}\n.bg11 {background: linear-gradient(94deg, #f9f7e9 80%, #dff0fb 100%);}\n.bg12 {background: linear-gradient(90deg, #eaf3fc 85%, #e0ecf9 100%);}\n.drugguide-subtitle {\n  font-size: 1.23em;\n  color: #388abb;\n  font-weight: bold;\n  letter-spacing: 0.5px;\n  padding-left: 6px;\n  margin: 0 0 14px 0;\n  position:relative;\n  z-index: 2;\n  display: flex;\n  align-items: center;\n}\n.drugguide-subtitle span {\n  display: inline-block;\n  width: 28px;\n  height: 28px;\n  font-size: 1em;\n  color: #fff;\n  background: #a3d7ee;\n  border-radius: 100%;\n  text-align: center;\n  line-height: 28px;\n  margin-right: 13px;\n  font-weight: bold;\n  box-shadow: 0 2px 7px 0 rgba(163,215,238,0.23);\n}\n.drugguide-content {\n  position: relative;\n  z-index: 2;\n  padding: 22px 18px 16px 18px;\n  background: rgba(255,255,255,0.88);\n  border-radius: 10px;\n  box-shadow: 0 2px 15px 0 rgba(125,170,220,0.04);\n}\n.drugguide-content ul {\n  margin-left: 18px;\n  margin-top:10px;\n  margin-bottom:8px;\n}\n.drugguide-content li {\n  padding-bottom: 7px;\n  font-size: 0.99em;\n}\n.drugguide-tip {\n  display: block;\n  background: #f6faf8;\n  border-left: 4px solid #a3d7ee;\n  color: #317876;\n  padding: 6px 13px;\n  margin-top: 11px;\n  margin-bottom: 4px;\n  border-radius: 4px;\n  font-size: 0.98em;\n}\n.drugguide-emphasize {\n  font-weight: bold;\n  color: #de8412;\n  background: #fff4e5;\n  border-radius: 5px;\n  padding: 4px 11px;\n  margin-top:8px;\n  display: inline-block;\n  font-size: 1.01em;\n}\n.drugguide-refdata {\n  color: #7d97b8;\n  font-size: 0.94em;\n  vertical-align: super;\n  margin-left:2px;\n}\n.drugguide-references ol {\n  margin-left:16px;\n}\n.drugguide-references li {\n  font-size:0.97em;\n  margin-bottom:6px;\n  color: #466a92;\n}\n@media (max-width: 690px) {\n  .drugguide-container {padding:10px 2% 25px 2%;}\n  .drugguide-title {font-size: 1.3em;}\n  .drugguide-section {margin-bottom:22px;}\n  .drugguide-subtitle {font-size: 1em;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"drugguide-container\">\n  \u003Ch1 id=\"material_title\" class=\"drugguide-title\">胰腺癌药品实用用药指南：安全、规",462,"2025-12-05 00:07:32","吉西他滨用药安全手册——胰腺癌治疗中的关键细节","吉西他滨, 胰腺癌, 化疗药物, 用药安全, 不良反应, 特殊人群用药","本文将深度解析吉西他滨的安全用药约定，提供有效的用法用量、注意事项，为胰腺癌患者赋能，以最大化治疗效果。","2025-12-16 11:31:50",2,[35],{"menuId":36,"menuName":37,"parentId":21,"orderNum":33,"path":38,"component":39,"isFrame":40,"isCache":41,"menuType":42,"visible":43,"status":21,"createDept":6,"remark":23,"createTime":44,"children":45,"columnImage":46,"columnLogo":47,"uncheckedLogo":6,"checkedLogo":6,"isHot":43,"isHome":21,"forceLogin":21,"color":48,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":38,"componentInfo":39},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":57,"success":55},{"pageNo":43,"pageSize":58,"result":59,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":61,"success":55},{"authors":62,"appraiseDimensionScoresVos":63},[],[]]